文献速递冠心病

胰岛素与非胰岛素治疗的2型糖尿病患者PCI后主要不良心血管事件比较

Major Adverse Cardiovascular Events in Insulin‐ Versus Non‐Insulin‐Treated Type 2 Diabetes Patients Following Percutaneous Coronary Intervention: A Prospective Cohort Study
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-10-14

该单中心前瞻性队列研究纳入465例接受经皮冠状动脉介入治疗并完成1年随访的2型糖尿病患者,按降糖方案分为胰岛素治疗组与非胰岛素治疗组。主要终点为主要不良心血管事件,包括非致死性心肌梗死、卒中、冠状动脉旁路移植术、再次PCI和死亡。结果显示胰岛素治疗组MACE发生率高于非胰岛素治疗组,但差异未达到统计学显著性。

要点

  • 胰岛素治疗的2型糖尿病患者PCI后1年MACE发生率为12.5%,高于非胰岛素治疗组的7.5%
  • 胰岛素治疗组再次PCI和卒中发生率均高于非胰岛素治疗组
  • 胰岛素治疗组与非胰岛素治疗组MACE风险差异未达到统计学显著性

核心结论

  • 胰岛素治疗的2型糖尿病患者PCI后不良心血管事件发生率高于非胰岛素治疗患者,提示胰岛素治疗患者可能是PCI后MACE的较高风险人群

研究设计与样本

  • 单中心前瞻性队列研究,纳入465例接受PCI并完成1年随访的2型糖尿病患者
  • 按降糖治疗方式分为胰岛素治疗组与非胰岛素治疗组
  • 主要终点为MACE,定义为非致死性心肌梗死、卒中、冠状动脉旁路移植术、再次PCI和死亡的复合终点

主要发现

  • 胰岛素治疗组MACE发生率为12.5%,非胰岛素治疗组为7.5%
  • 胰岛素治疗组再次PCI发生率为4.8%,非胰岛素治疗组为2.5%
  • 胰岛素治疗组卒中发生率为3.8%,非胰岛素治疗组为1.4%
  • Kaplan-Meier分析显示胰岛素治疗组12个月内MACE累积发生率较高,Log rank p = 0.113

关键数值与推荐

  • 未校正OR = 1.743,95% CI: 0.865–3.512,p = 0.120
  • 校正后OR = 1.729,95% CI: 0.822–3.635,p = 0.149
  • 未校正HR = 1.695,95% CI: 0.874–3.284,p = 0.118
  • 校正后HR = 1.554,95% CI: 0.793–3.045,p = 0.199

临床怎么用

  • 对于接受胰岛素治疗的2型糖尿病患者,PCI术后应加强心血管事件风险监测
  • 胰岛素治疗组再次PCI和卒中发生率相对较高,临床随访中需重点关注

局限性

  • 单中心研究,样本量为465例
  • 主要终点差异未达到统计学显著性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Insulin-treated type 2 diabetes millatus (ITDM) is associated with heigher cardiovascular risk profile. However its impact on major adverse cardiovascular events (MACE) following poorer percutaneous coronary intervention (PCI) remains unclear. Aims This study aimed to evaluate major adverse cardiovascular events in insulin-treated diabetes mellitus (ITDM) and non-insulin-treated diabetes mellitus (Non-ITDM) type 2 diabetes mellitus (T2DM) patients' post-PCI. Methods A single-center prospective cohort study was conducted in which 465 T2DM patients undergoing PCI and completing the 1-year follow-up were enrolled. Patients were divided into two groups based on their therapy for DM: ITDM and Non-ITDM. The primary endpoint was MACE, a composite of non-fatal myocardial infarction (MI), stroke, coronary artery bypass grafting (CABG), repeat PCI, and mortality. Results Logistic regression confirmed higher odds of MACE among ITDM compared to Non-ITDM patients (unadjusted OR = 1.743, 95% CI: 0.865–3.512, p = 0.120; adjusted OR = 1.729, 95% CI: 0.822–3.635, p = 0.149). Kaplan–Meier analysis illustrated increased cumulative incidence of MACE among ITDM over 12 months (Log rank p = 0.113). Similarly, Cox proportional hazards analysis reported higher hazard ratios in the insulin-treated group (unadjusted HR = 1.695, 95% CI: 0.874–3.284, p = 0.118; adjusted HR = 1.554, 95% CI: 0.793–3.045, p = 0.199). Yet the results were not statistically significant. Overall, a higher incidence of MACE was reported among ITDM (12.5%) compared to Non-ITDM (7.5%), particularly repeat PCI (4.8% vs. 2.5%) and stroke (3.8% vs. 1.4%) among T2DM patients after PCI. Conclusion T2DM patients receiving insulin therapy had a higher incidence of adverse cardiovascular events compared to those not on insulin treatment, that insulin-treated patients may represent a higher-risk group for MACE following PCI.

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:Major Adverse Cardiovascular Events in Insulin‐ Versus Non‐Insulin‐Treated Type 2 Diabetes Patients Following Percutaneous Coronary Intervention: A Prospective Cohort Study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。